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Abstract
Background: A study was made to identify the most effective protocol for reducing the risk of osteonecrosis of 
the jaws (ONJ) following tooth extraction in patients subjected to treatment with antiresorptive or antiangiogenic 
drugs.
Material and Methods: A MEDLINE and SCOPUS search (January 2003 - March 2015) was made with the pur-
pose of conducting a systematic literature review based on the Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) guidelines. All articles contributing information on tooth extractions in patients 
treated with oral or intravenous antiresorptive or antiangiogenic drugs were included.
Results: Only 13 of the 380 selected articles were finally included in the review: 11 and 5 of them offered data on 
patients treated with intravenous and oral bisphosphonates, respectively. No randomized controlled trials were 
found – all publications corresponding to case series or cohort studies. The prevalence of ONJ in the patients 
treated with intravenous and oral bisphosphonates was 6,9% (range 0-34.7%) and 0.47% (range 0-2.5%), respec-
tively. The main preventive measures comprised local and systemic infection control.
Conclusions: No conclusive scientific evidence is available to date on the efficacy of ONJ prevention protocols in 
patients treated with antiresorptive or antiangiogenic drugs subjected to tooth extraction.
Key words: Bisphosphonates, angiogenesis inhibitors, antiresorptive drugs, extraction, osteonecrosis.
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Introduction
Medication-related osteonecrosis of the jaws (ONJ) is 
defined as an area of exposed bone or bone that can be 
probed through an intra- or extraoral fistula in the max-
illofacial region, persisting for over 8 weeks in patients 
receiving or who have received antiresorptive or antian-
giogenic medication, and who have not undergone ra-
diotherapy or present evidence of metastatic disease in 
the mentioned anatomical region (1). Once such lesions 
become established, their management is complicated 
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and the course of the disease is difficult to predict – par-
ticularly in the most advanced cases (2). Prevention and 
control of the risk factors is therefore especially impor-
tant. Osteonecrosis of the jaws may develop spontane-
ously or can be induced by invasive dental procedures 
(3), fundamentally tooth extractions (4,5). The exact 
prevalence of ONJ after tooth extraction is not clear, 
though according to the American Association of Oral 
and Maxillofacial Surgeons, two out of every three cas-
es are related to oral surgery – particularly tooth extrac-
tion (6).
A number of perioperative measures have been proposed 
for preventing this complication, including antiseptic 
rinses immediately before extraction and until healing 
of the socket (7), antibiotic prophylaxis (8), alveoloplasty 
with primary closure (9), fibrin or autologous platelet-
rich plasma (9), atraumatic extraction with orthodontic 
traction (10,11), ozone therapy (12), limitation of the 
number of extractions performed in each session (13), 
etc. Many of these proposed measures are fundamented 
upon personal experience and on consensus documents 
developed by scientific societies (1,6-9,13-20) (Table 1), 
and their true efficacy is not known (21).
In view of the increasing number of patients receiv-
ing antiresorptive or antiangiogenic treatment, and the 
important morbidity associated to ONJ, we decided to 
conduct a systematic review with the purpose of identi-
fying the most relevant protocols and best measures for 
preventing the development of ONJ secondary to tooth 
extraction.
Material and Methods
The present systematic review was carried out following 
the Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) guidelines (22). The 
PICO (Patient, Intervention, Comparison, Outcome) 
question that guided the review was: What is the most 
effective procedure for reducing the risk of ONJ after 
tooth extraction in patients receiving treatment with 
antiresorptive or antiangiogenic drugs?
- Search strategy
A systematic MEDLINE and SCOPUS database search 
(January 2003 - March 2015) was made to identify 
publications eligible for inclusion in the study, using a 
combination of MeSH terms and free text (Table 2) as 
search strategy: “diphosphonates”, “bisphosphonates”, 
“antiresorptive”, “angiogenesis inhibitors” “angiogen-
esis”, “inhibitors”, “antiangiogenic”, “denosumab”, “su-
nitinib”, “tooth extraction”, “tooth”, “dental extraction”, 
“dental”, “extraction, “osteonecrosis”. As a complement 
to this search, we conducted a manual evaluation of ar-
ticles included in the references of the identified full-
text publications, with the selection of those citations 
considered to be of relevance.
- Selection of studies
In order to assess the eligibility of the studies, two re-
viewers (MD, JL) traced the titles and abstracts of the 
publications generated by the search strategy. The full-
text articles were retrieved in the case of those studies 
that appeared to satisfy the screening criteria, and in 
the case of those which offered too little information in 
the title / abstract to firmly decide inclusion of the study 
or not. All articles contributing information on tooth 
extractions in patients treated with oral or intravenous 
antiresorptive or antiangiogenic drugs were included. 
The selected studies assessed the efficacy of a protocol 
for reducing the incidence of ONJ after tooth extraction, 
and were required to supply information on the type of 
antiresorptive or antiangiogenic treatment used, the ad-
ministration route (intravenous or oral), the indication 
of treatment, a clear definition of the presence of ONJ, 
and the duration of follow-up (in months). The articles 
also were required to clearly specify the prevention pro-
tocol employed (surgical technique, type and dose of 
antibiotic administered, etc.).
Studies in patients under 18 years of age administered 
bisphosphonates (BPs) due to osteogenesis imperfecta 
were excluded, as were case series involving fewer than 
10 patients, and animal studies. In the case of studies 
involving expansions of the same series of patients, only 
the most recent data were considered.
The two reviewers independently assessed compliance 
with the inclusion and exclusion criteria. The reason for 
exclusion was recorded in the case of those articles that 
were eliminated in this phase.
- Data extraction
The identified references were processed using the bib-
liographic management program Refworks (Proquest), 
and the data extracted from the articles were entered in 
a MS Excel spreadsheet. The studies were divided into 
three groups: (a) studies involving patients treated with 
intravenous BPs; (b) studies involving patients treated 
with oral BPs; and (c) studies involving patients treated 
with other antiresorptive or antiangiogenic drugs. The 
main variables analyzed in each study were: authors, 
date of publication, sample size, drug type, dose and 
administration route, indication and, number of extrac-
tions and their location (maxilla or mandible), the pre-
ventive protocol employed (antibiotic prophylaxis, sur-
gical technique and local measures), and the appearance 
of ONJ.
Results and Discussion
The article screening process is schematically shown in 
figure 1. Following the systematic search and the elimi-
nation of duplicate publications, we identified a total of 
380 articles, of which 358 were discarded after assess-
ing the title or abstract. Of the remaining 22 full-text 
articles, we eliminated 9 that failed to meet the inclu-
sion criteria (Fig. 1), leaving a final total of 13 publica-
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Authors, year (ref.) Expert panel or endorsed  by scientific societies Recommendations 
Sambrook et al. 
2006 (14) 
Australian and New Zealand Bone and 
Mineral Society  
Osteoporosis Australia 
Medical Oncology Group of Australia 
Australian Dental Association 
BP-IV or Oral: 
Minimum flap raising 
Minimum bone trauma 
Suture 
Single 2 g dose of amoxicillin before extraction 
Bagán et al. 2007 
(8) 
Spanish Expert Panel in Oncology, 
Hematology, Urology and Stomatology 
BP-IV:  
Atraumatic extraction 
Suture and primary closure 
875/125 mg amoxicillin-clavulanate/8 h x 12 days (2 before and 10 after) 
300 mg clindamycin/6 h x 12 days (2 before and 10 after) 
Chlorhexidine 0.12%/12 h x 15 days 
Interruption of BPs due to medical criterion 
Tubiana-Hulin   
et al. 2007 (9) French Expert Panel  
BP-IV:  
Antibiotic prophylaxis 
Fibrin or autologous platelet rich plasma 
Bone regularization 
Primary closure 
Khosla et al. 2007 
(17) 
American Society for Bone and Mineral 
Research (ASBMR) 
BP-IV:  
Extraction only in case of great mobility or infection 
No specific protocol 
BF-Oral:  
Periodontal surgery with minimal bone remodeling 
No suspension of BP 
Fehm et al. 2009 
(18) German Society of Senology 
BP-IV or Oral: 
Antibiotic prophylaxis 1 day before and 3 days after 
Primary closure, mucosal flaps for bone coverage. 
BP-IV: 
Suspension of BP 6-8 weeks before and after, according to systemic 
conditions 
Yoneda et al. 2010 
(19) 
Allied Task Force Committee of Japanese 
Society for Bone and Mineral Research 
Japanese Osteoporosis Society 
Japanese Society of Periodontology 
Japanese Society of Oral and 
Maxillofacial Surgeons 
… and other scientific societies 
Previous bacterial plaque removal 
Antibiotic before, during and after operation 
Socket suture 
BP-IV: 
No suspension of BP 
BF-Oral:  
< 3 years of administration and no risk factors 
No change in treatment 
> 3 years of administration or < 3 years with risk factors 
Possibility of suspending treatment until healing is completed  
Hellstein et al. 
2011 (13) American Dental Association (ADA) 
Avoidance of extractions (crown amputation and root endodontic treatment 
preferred) 
Primary closure or placement of semi-permeable membranes on socket 
Chlorhexidine/12 h x 4-8 weeks (until healing) 
Antibiotics 1 day before and up to 3-7 days after the procedure 
Consultation with physician about possibility of suspending BP 
Ruggiero et al.2014 
(1) 
American Association of Oral and 
Maxillofacial Surgeons (AAOMS) 
BP-IV:  
Avoidance of extractions (crown amputation and root endodontic treatment 
preferred) 
BF-Oral: 
< 4 years of administration and no risk factors 
No change in treatment 
Informed consent 
Routine controls 
< 4 years of administration and with corticosteroids 
Consider suspending treatment 2 months before and until bone healing is 
complete 
> 4 years of administration 
Consider suspending treatment 2 months before and until bone healing is 
complete 
Khan et al. 2015 
(20) 
Canadian Association of Oral and 
Maxillofacial Surgeons  
International Bone and Mineral Society 
… and other scientific societies 
BP-IV:  
Interrupt BP 3-6 months if allowed by patient condition  
BF-Oral:  
Interrupt BF-Oral for invasive oral surgery or in patients with multiple risk 
factors, if allowed by clinical condition 
Table 1. Principal protocols for the prevention of osteonecrosis of the jaws (ONJ) associated to the administration of antiresorptive or 
antiangiogenic drugs in patients subjected to oral surgery.
BP-IV: patients administered intravenous bisphosphonates; BF-Oral: patients administered oral bisphosphonates.
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tions. Of these, 11 and 5 offered data on patients treated 
with intravenous and oral BPs, respectively (Tables 3, 3 
continue,4). No articles on the prevention of ONJ in pa-
tients treated with other antiresorptive or antiangiogenic 
drugs were included. All the included publications were 
case series or cohort studies; we found no randomized 
controlled trials. 
The studies involving subjects treated with intravenous 
BPs included a total of 634 patients, with a prevalence 
of ONJ of 6,9% (range 0-34.7%). In turn, the studies in-
volving oral BPs included a total of 1261 patients, with 
a prevalence of ONJ of 0.47% (range 0-2.5%). The main 
preventive measures comprised local and systemic in-
fection control (Tables 3, 3 continue,4). 
Although medication-related ONJ may manifest spon-
taneously, in up to 80% of all cases it is associated to 
tooth extractions or other surgical procedures involving 
bone exposure. In this study we therefore considered ex-
traction as a potential risk factor for ONJ. Our findings 
show that few authors have systematically applied any 
of the prophylactic protocols proposed by the different 
international expert committees or scientific societies 
(1,6-9,13-20). Most articles on the efficacy of preventive 
measures before tooth extraction in patients treated with 
antiresorptive or antiangiogenic drugs have methodo-
logical shortcomings, are not randomized or controlled, 
involve an insufficient sample size, and apply very het-
erogeneous preventive protocols – combining common 
sense initiatives such as antibiotic treatment with other 
much more sophisticated strategies such as platelet rich 
plasma or low-power laser irradiation. This heterogene-
ity and the limitations of the reviewed studies therefore 
do not allow quantitative analysis (meta-analysis).
- Bisphosphonates via the intravenous route
Lodi et al. (23) were probably the first authors to pro-
pose a specific protocol for tooth extraction in patients 
treated with intravenous BPs, based on local and sys-
temic infection control measures. These investigators 
conducted a prospective study of 23 patients subjected 
to 38 extractions, and identified no cases of ONJ over 
a minimum follow-up period of 12 months. In view of 
these results, they concluded that the conduction of a 
randomized, placebo-controlled trial without the appli-
cation of local and systemic infection control measures 
would not be ethically acceptable.
Following the work of Lodi et al. (23), new both retro-
spective and prospective studies were made, applying 
local and systemic infection control measures. In these 
publications the prevalence of ONJ varied between 
0-23.5% (24-29). Shared features of these studies were 
the provision of antibiotic prophylaxis; atraumatic tooth 
extraction with the raising of a flap to allow first-inten-
tion closure and healing, minimizing direct contact of 
the oral bacteria with the socket; and the local applica-
tion of antiseptic products. However, the composition P
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of the antimicrobials used, the dosage and the duration 
of treatment varied considerably (Table 3, 3 continue). 
Although randomized trials would be needed to deter-
mine the true efficacy of antibiotic prophylaxis in pa-
tients subjected to extraction and treated with antire-
sorptive or antiangiogenic drugs, antibiotics do appear 
to exert a certain preventive effect, as demonstrated by 
some studies in animals (30) and retrospective stud-
ies in patients with multiple myeloma (5). Mozzati et 
al. (31) conducted a prospective study of 176 patients 
subjected to a total of 542 extractions, and randomized 
to two groups: in one group surgery involved the rais-
ing of a mucoperiosteal flap to allow first-intention clo-
sure and healing, while in the other group extraction 
was carried out based on the same protocol but placing 
plasma rich in growth factors in the socket before first-
intention closure. After a follow-up period of between 
24-60 months, they recorded 5 cases of ONJ (1.8%) in 
the first group and none in the second.
Scoletta et al. (32) proposed the use of autologous plasma 
rich in growth factors associated to systemic antibiotic 
treatment in order to accelerate the healing process. In 
their initial protocol, the authors raised a mucoperiosteal 
flap to allow healing by first intention. In a prospective 
study involved 65 patients subjected to 220 extractions, 
they documented ONJ in 7.6% of the cases (represent-
ing 2.2% of the extractions made). These same authors 
subsequently improved their protocol, eliminating the 
mucoperiosteal flap and performing cross-suturing over 
the socket in order to maintain the stability of the plas-
ma rich in growth factors (33). With this new protocol, 
the authors were able to reduce the prevalence of ONJ to 
1.5% of the patients and 0.9% of the extractions - in ad-
dition to simplifying the technique and shortening the 
surgery time. In a recent meta-analysis on the role of 
autologous platelet concentrates in the prevention and 
treatment of ONJ related to BPs, Del Fabbro et al. (34) 
concluded that although the published evidence is still 
weak, these products might offer benefits in terms of the 
prevention of ONJ in patients undergoing oral surgery.
Recently, Vescovi et al. (35) proposed a protocol in-
volving low-power laser irradiation associated to anti-
biotic prophylaxis. Specifically, the proposal included 
Nd:YAG laser biostimulation immediately after extrac-
tion and then on a weekly basis until 6 weeks or closure 
of the surgical wound. On applying this protocol to a 
series of 91 cancer patients receiving intravenous BPs, 
the authors recorded ONJ in 5 patients (5,5%)(represent-
ing 1.8% of the 271 extractions made).
- Bisphosphonates via the oral route
The relationship between intravenous BPs and ONJ 
is fundamented upon solid epidemiological evidence, 
though the association between ONJ and oral BPs has 
been subject to strong controversy. Nevertheless, recent 
studies appear to offer tangible evidence of such an as-
sociation (36). Since osteoporotic patients require pro-
longed treatment, the cases of ONJ related to oral BPs 
have increased, and a recent retrospective multicenter 
study suggests that the relative frequency of ONJ in os-
teoporotic patients treated with oral BPs is greater than 
previously believed (37). In the same way as in intra-
venous bisphosphonate therapy, the strategies proposed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Articles identified in the MEDLINE and 
SCOPUS databases 
(n = 380) 
Full-text articles evaluated 
(n = 22) 
Full-text articles excluded 
(n=9) 
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(n=1) Patients with established ONJ 
(n=1) Letter to the editor. Not a study of results 
Articles included in the qualitative analysis 
(n =13) 
Excluded on the basis of the title and/or abstract 
(n = 358) 
 
 
 
 
Fig. 1. Schematic representation of the publication screening and inclusion process.
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for preventing ONJ in patients receiving oral BPs are 
based on local and systemic infection control (Table 4). 
Mozzati et al. (38) conducted a prospective study of 700 
patients subjected to a total of 1480 extractions, rand-
omized to two groups: in one group surgery involved the 
raising of a mucoperiosteal flap to allow first-intention 
closure and healing, while in the other group extraction 
was carried out without the raising of a flap and placing 
reabsorbable hemostatic sponge material in the socket 
to protect the wound. After 12-72 months of follow-up, 
no cases of ONJ were observed in either group.
The drug holiday concept (temporary suspension of the 
medication) in patients receiving oral BPs have been 
the subject of debate (1). The consensus document pub-
lished by the American Association of Oral and Maxil-
lofacial Surgeons in 2006 recommended interruption of 
the treatment from three months before to three months 
after extraction, if allowed by the systemic conditions 
of the patient (6). The 2014 update on this document 
(1) reduced the drug holiday period before extraction 
to two months, with application of this protocol only 
to patients who had received BPs for over four years. 
Hasegawa et al. (39) in turn conducted a retrospective 
study of 201 patients treated with oral BPs and subject-
ed to a total of 434 tooth extractions. The patients were 
randomized to two groups: in one group oral BPs were 
suspended for three months before extraction, while no 
treatment interruption was applied in the other group. 
The authors identified a single case of ONJ in the latter 
group (0.6%) and none in the group in which oral BPs 
were temporarily suspended. 
There is no evidence that the interruption of oral BPs 
is able to eliminate the risk of ONJ. On the other hand, 
temporary suspension of the medication may have a 
negative impact in terms of bone resorption. It is there-
fore necessary to consider the risks of the dental proce-
dure and discuss the possibility of suspending antire-
sorptive treatment with the prescribing physician (13). 
Furthermore, in our setting, a significant percentage 
of patients receiving oral BPs and who visit the dentist 
for extractions do not meet the criteria for prescribing 
bisphosphonate therapy (40). As a result, patient re-
evaluation by the physician should be considered, along 
with possible suspension of the treatment before dental 
surgery is carried out.
Regarding other prophylactic measures, Vescovi et al. 
(35), on using the laser treatment described above in re-
lation to patients receiving intravenous BPs, recorded 
no cases of ONJ in 126 patients administered oral BPs 
and subjected to tooth extraction.
No conclusive scientific evidence is available to date on 
the efficacy of ONJ prevention protocols in patients sub-
jected to tooth extraction and treated with antiresorp-
tive or antiangiogenic drugs. In practical terms, and 
until future studies are able to define the ideal proto-
col, adoption of the preventive measures proposed by 
the international expert committees has weak scientific 
justification, but could afford some coverage from the 
medical-legal perspective.
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